GlassScriptPhysician profile
Jacqueline M Jackson
NPI 1083118350
$5,919.22
in general payments reported to CMS, 2019-2025
34 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $1,091 · 2023: $940 · 2024: $1,867 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $983.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $786.13 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $633.15 | 2021-2025 | |
| Abbvie INC. | $546.35 | 2021-2025 | |
| Amgen INC. | $402.69 | 2021-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $269.65 | 2021-2025 | Trelegy Ellipta, Boostrix, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $250.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.66 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $218.93 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.08 | 2021-2025 | Trintellix |
| Corcept Therapeutics | $139.20 | 2021-2025 | Korlym |
| Dexcom, INC. | $133.78 | 2021-2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $120.46 | 2023 | Ingrezza |
| Ironwood Pharmaceuticals, INC | $115.35 | 2022-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.53 | 2024-2025 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.56 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $89.54 | 2025 | Voquezna |
| Radius Health, INC. | $81.95 | 2024-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $70.57 | 2025 | Spravato |
| Astellas Pharma US INC | $56.44 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $50.47 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $40.20 | 2021-2025 | Zoryve |
| Esperion Therapeutics, INC. | $36.40 | 2024 | Nexletol |
| Exact Sciences Corporation | $36.10 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $33.02 | 2023-2024 | |
| Allergan, INC. | $32.04 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.53 | 2022 | |
| Edwards Lifesciences Corporation | $28.90 | 2022 | |
| Boston Scientific Corporation | $27.50 | 2022-2023 | Watchman |
| Currax Pharmaceuticals LLC | $24.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.31 | 2021 | |
| Daiichi Sankyo INC. | $20.30 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.22 | 2021 | |
| Inogen, INC. | $6.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.